BIM
CBAY

Bogle Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Bogle Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-203,580
Closed -$1.64M – 373
2017
Q3 		$1.64M Buy
+203,580
New +$1.38M 0.11% 175

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bogle Investment Management's CBAY Position: Q4 2017 in Review

Bogle Investment Management sold out of Cymabay Therapeutics (CBAY) in Q4 2017, closing a stake of 203,580 shares — an estimated $1.64M sold.

Bogle Investment Management first reported a position in CBAY in Q3 2017 and held it in 1 quarter. The position peaked at $1.64M in Q3 2017. 80 funds tracked by Wall St. Rank hold CBAY as of Q4 2017.

  • Bogle Investment Management reported no remaining Cymabay Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Bogle Investment Management sold 203,580 Cymabay Therapeutics shares in Q4 2017, an estimated $1.64M.
  • Bogle Investment Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 1 quarter.
  • Bogle Investment Management's Cymabay Therapeutics position peaked at $1.64M in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2017.

Based on Bogle Investment Management's 13F filing for Q4 2017, filed 13 Feb 2018.